#Cambridge #United Kingdom #Biofidelity #CellCarta #Aspyre Lung

CellCarta and Biofidelity Partner for Lung Cancer Testing

In a significant development in the realm of targeted cancer treatment, CellCarta and Biofidelity have announced an exclusive global strategic partnership for the Aspyre® Lung platform. This collaboration, which builds upon their existing relationship, aims to revolutionize lung cancer clinical trials by simplifying the testing processes and making them more efficient.

The Aspyre® Lung platform is specifically designed to enhance biomarker testing, which is crucial for guiding patient enrollment and treatment decisions in lung cancer trials. Traditional next-generation sequencing (NGS) methods often take weeks to yield results and come with high failure rates; in fact, about 25% of lung cancer samples do not successfully complete NGS testing. Furthermore, the costs associated with these methods can be a significant burden. Therefore, there is a pressing need for a more efficient solution that can deliver quicker results without compromising quality.

Aspyre Lung addresses these challenges by providing actionable genomic alterations (AGA) tailored for lung cancer. This innovative assay allows sponsors to quickly identify suitable candidates for biomarker-driven trial arms while excluding those who do not meet the criteria. Notably, Aspyre Lung can process both tissue and blood samples with minimal specimen input, significantly cutting down the turnaround time to just four to five days. This expedited process comes with an impressive success rate of up to 99%, making it a more viable option compared to broad NGS methods.

Robin Grimwood, SVP of Genomics at CellCarta, expressed enthusiasm about this exclusive arrangement, stating, "Becoming the exclusive clinical trial partner for Aspyre Lung is a major advancement in our partnership with Biofidelity. We are establishing a more coordinated framework for deploying Aspyre Lung in global clinical trials, positioning ourselves well for future collaborations on emerging assays like Enspyre®, which is centered around minimal residual disease (MRD) technology."

This partnership not only streamlines the deployment of Aspyre Lung but also reinforces the coordination between assay expertise and clinical trial delivery. As a result, sponsors can expect reduced operational friction when integrating targeted testing into their programs.

In his remarks, Barnaby Balmforth, CEO of Biofidelity, remarked, "This expanded partnership reflects our mutual dedication to simplifying the integration of targeted genomic technologies into clinical trials. CellCarta has proven its reliability and operational excellence in global clinical trial testing. Together, we aim to lower the barriers to adoption, enabling sponsors to more easily include targeted lung cancer testing in their trials."

CellCarta stands out as a leading global Contract Research Organization (CRO) known for its extensive range of biomarker testing services and its commitment to quality. With facilities and accreditations spanning across Canada, the USA, Belgium, Australia, and China, CellCarta supports the entire drug development cycle, from discovery through to late-stage clinical trials.

Biofidelity, on the other hand, is committed to improving cancer treatment outcomes through advanced genomic technologies that allow for better targeting of therapies and early detection of treatment resistance. Their innovative approaches support routine monitoring of treatment response, ultimately aiming to enhance patient lives.

This partnership marks a substantial step forward in lung cancer diagnostics, potentially changing the landscape of clinical trials for the better. As both companies look ahead, they are poised to tackle new challenges and drive advancements in genomics that will benefit patients and healthcare providers alike.

For further information on Biofidelity's Aspyre Lung, you can visit Biofidelity's website.

To learn more about CellCarta's capabilities as a CRO, you can visit CellCarta's website.